CENTURA PENROSE HOSPITAL
1. Target Overview & Investment Thesis
CENTURA PENROSE HOSPITAL is a 484-bed suburban community hospital in EL PASO, CO with $809.7M in net patient revenue and a 0.2% operating margin. The hospital serves a payer mix of 20.7% Medicare, 22.1% Medicaid, and 57.2% commercial.
Thesis: Undervalued. Our ML models identify $59.6M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 0.2% to 7.5% (+736bps).
| Net Revenue HCRIS | $809.7M |
| Current EBITDA COMPUTED | $1.2M |
| Operating Margin COMPUTED | 0.2% |
| Occupancy HCRIS | 66.8% |
| Revenue / Bed COMPUTED | $1.7M |
| Net-to-Gross HCRIS | 17.9% |
| Distress Probability ML | 47.7% |
2. Market Context & Competitive Position
CO has 108 Medicare-certified hospitals with a median operating margin of -3.6%. The target's margin of 0.2% places it above the state median. Among 13 size-comparable peers (242-968 beds), the median margin is 3.5%. The target's below-peer margin suggests operational improvement opportunity.
3. RCM Performance Analysis — Comparable Hospitals
Comps selected by bed count (242-968), prioritizing same-state peers. 13 hospitals in the comp set.
| Hospital | State | Beds | Revenue | Margin |
|---|---|---|---|---|
| CENTURA PENROSE HOSPITAL (Target) | CO | 484 | $809.7M | 0.2% |
| UNIVERSITY OF CO HOSPITAL | CO | 709 | $2.66B | 1.8% |
| CHILDRENS HOSPITAL COLORADO | CO | 486 | $1.42B | -2.3% |
| MEMORIAL HEALTH SYSTEM | CO | 501 | $1.11B | 3.5% |
| DENVER HEALTH MEDICAL CENTER | CO | 396 | $1.11B | -8.1% |
| SWEDISH MEDICAL CENTER | CO | 351 | $670.0M | 23.8% |
| PRESBYTERIAN ST. LUKES MEDICAL | CO | 287 | $646.0M | 27.6% |
| SAINT JOSEPH HOSPITAL | CO | 400 | $567.5M | -6.1% |
| SKY RIDGE MEDICAL CENTER | CO | 273 | $544.7M | 28.9% |
4. Predicted Improvement Opportunities
Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $59.6M (736bps margin improvement).
| Lever | Current | Target | EBITDA Impact | Margin | Ramp |
|---|---|---|---|---|---|
| Net Collection Rate | 93.5% | 97.0% | $17.0M | +210bp | 18mo |
| Cost to Collect | 4.5% | 2.5% | $16.2M | +200bp | 12mo |
| Denial Rate Reduction | 12.0% | 6.5% | $16.0M | +198bp | 12mo |
| A/R Days Reduction | 5200.0% | 3800.0% | $9.9M | +122bp | 9mo |
| Clean Claim Rate | 88.0% | 96.0% | $518K | +6bp | 6mo |
5. EBITDA Bridge
| Current EBITDA | $1.2M |
| + RCM Uplift | +$59.6M |
| Pro Forma EBITDA | $60.8M |
| Current Margin | 0.2% |
| Pro Forma Margin | 7.5% |
| WC Released (1x) | $31.1M |
6. Returns Analysis — Scenario Matrix
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.
| Scenario | Entry | Exit | Equity In | Equity Out | MOIC | IRR |
|---|---|---|---|---|---|---|
| Base Case | 10.0x | 10.0x | $1.9M | $604.2M | 316.62x | 216.3% |
| Base (11x exit) | 10.0x | 11.0x | $1.9M | $665.2M | 348.61x | 222.4% |
| Bull Case | 9.0x | 11.0x | $1.7M | $862.5M | 502.22x | 246.9% |
| Bull (12x exit) | 9.0x | 12.0x | $1.7M | $941.4M | 548.18x | 253.0% |
| Bear Case | 11.0x | 10.0x | $2.1M | $305.6M | 145.57x | 170.8% |
| Bear (11x exit) | 11.0x | 11.0x | $2.1M | $336.8M | 160.45x | 176.1% |
7. Key Risks & Mitigants
| Severity | Risk Factor | Mitigant |
|---|---|---|
| Medium | Elevated Medicaid exposure (22.1%) | Medicaid reimburses below cost in most states. Mitigant: denial reduction lever has highest impact on Medicaid claims |
| Low | Low net-to-gross ratio | Large contractual allowances suggest pricing discipline issues. Mitigant: payer renegotiation is an additional upside lever |
8. Data Sources & Methodology Appendix
Data Sources
- CMS HCRIS Cost Reports (Medicare-certified hospitals)
- CMS Medicare Utilization (DRG-level volumes)
- CMS Chronic Conditions (county-level disease prevalence)
- HCRIS multi-year trend data (financial time series)
Comparable Selection
- 13 hospitals with 242-968 beds
- Same-state prioritization (n=14)
- Comp margins: P25=-6.1% / P50=3.5% / P75=22.0%
Bridge Methodology
- Targets: P75 of comparable peers (60% gap closure)
- Denial: avoidable share = 35% of delta × NPR
- AR: bad debt coefficient = $0.65 per day per $1K NPR
- NCR: 60% coefficient on collection rate improvement
- CDI: 0.75% of Medicare revenue per 0.01 CMI point
Returns Assumptions
- Leverage: 5.5x entry (84.6% debt / 15.4% equity)
- Organic growth: 3% annual EBITDA growth
- Debt paydown: 10% of principal per year
- Hold period: 5 years
Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.